Cambridge Newswire

Comprehensive Real-Time News Feed for Cambridge, MA.

Results 1 - 20 of 47 for "u:bloomberg.com" in Cambridge, MA

  1. Biogen Surges After Beating Estimates With Top Drug SalesRead the original story

    Wednesday Jan 27 | The Washington Post

    Biogen Inc. shares rose the most in three months on Wednesday after it said that sales of its top drug, a multiple sclerosis treatment, topped analysts' estimates and helped the company beat fourth-quarter projections amid a lackluster 2015. Sales of the treatment, Tecfidera, rose 5.9 percent from the previous quarter to the most ever.

    Comment?

  2. Biogen's Top Drug Has Record Quarter, Beats EstimatesRead the original story

    Wednesday Jan 27 | The Washington Post

    Biogen Inc. said that sales of its top drug, a multiple sclerosis treatment, rose 5.9 percent from the previous quarter, topping analysts' estimates after a lackluster year and helping the company beat projections of fourth-quarter earnings. The treatment, Tecfidera, has been a focus for investors as Biogen's biggest product and best bet for near-term revenue while the company waits on clinical trials of experimental drugs.

    Comment?

  3. Pharma Investors Look for Lessons After BioMarin FDA DefeatRead the original story

    Friday Jan 15 | The Washington Post

    The rejection of a BioMarin Pharmaceutical Inc. medication by U.S. regulators left patients and investors questioning how drugmakers could improve their chances for approval of treatments for diseases that afflict tiny segments of the population. The urgency grew even greater Friday for the Duchenne muscular dystrophy community after a Food and Drug Administration staff report cast doubt on the future of a second medication, saying there isn't enough evidence that Sarepta Therapeutics Inc.'s eteplirsen offers patients any real benefit.

    Comment?

  4. BioMarin's FDA Defeat Has Pharma Investors Looking for LessonsRead the original story

    Friday Jan 15 | The Washington Post

    The rejection of a BioMarin Pharmaceutical Inc. medication by U.S. regulators left patients and investors questioning how drugmakers could improve their chances for approval of treatments for diseases that afflict tiny segments of the population. The Food and Drug Administration's rationale for not clearing Kyndrisa Thursday left the door open for Sarepta Therapeutics Inc., which is taking a different approach to regulatory approval for another drug to treat Duchenne muscular dystrophy.

    Comment?

  5. Worst start to yearRead the original story w/Photo

    Jan 8, 2016 | Bloomberg

    The worst start to a year for global financial markets sparked the biggest weekly outflow of cash from equity mutual funds since September. Investors pulled $8.8 billion from funds that track stocks around the world, according to data collected by Cambridge, Massachusetts-based EPFR Global Inc., as the weakening of China's currency rekindled concern that slowing growth there would spread.

    Comment?

  6. Investors Pull $8.8 Billion From World Equity Funds in 2016 RoutRead the original story

    Jan 8, 2016 | The Washington Post

    The worst start to a year for global financial markets sparked the biggest weekly outflow of cash from equity mutual funds since September. Investors pulled $8.8 billion from funds that track stocks around the world, according to data collected by Cambridge, Massachusetts-based EPFR Global Inc., as the weakening of China's currency rekindled concern that slowing growth there would spread.

    Comment?

  7. Gene-Editing Drugmaker Backed by Google, Gates Files for IPORead the original story w/Photo

    Jan 5, 2016 | The Washington Post

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Editas Medicine Inc., the drugmaker whose backers include Bill Gates and Google Ventures, filed to become the first publicly traded company to specialize in a new technology to edit flaws in genes.

    Comment?

  8. Gene-Editing Drugmaker Backed by Google, Gates Files for Landmark IPORead the original story w/Photo

    Jan 4, 2016 | Bloomberg

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Editas Medicine Inc., the drugmaker whose backers include Bill Gates and Google Ventures, filed to become the first publicly traded company to specialize in a new technology to edit flaws in genes.

    Comment?

  9. Spending Bill Would Ban Drugs Made by Editing Human Embryo GenesRead the original story

    Dec 17, 2015 | The Washington Post

    Controversial gene-editing technologies on human embryos would be banned from approval by drug regulators under a $1.1 trillion spending bill the U.S. Congress is close to approving. Scientists and ethicists have called for similar measures, and the ban won't affect companies that are studying genome editing in mature, non-embryonic tissues.

    Comment?

  10. Sanofi in Asset Swap Talks With Boehringer for $25 Billion DealRead the original story

    Dec 15, 2015 | The Washington Post

    Sanofi is in exclusive talks to swap assets with Germany's Boehringer Ingelheim GmbH in a 22.8 billion-euro transaction that would be the largest for France's biggest drugmaker in more than a decade. Sanofi's animal-health business, valued at 11.4 billion euros, and Boehringer Ingelheim's consumer-health operations, at 6.7 billion euros, would be traded, according to a statement on Tuesday.

    Comment?

  11. New Weapon for Investors Appears in the War on Coal: PolitenessRead the original story

    Dec 9, 2015 | The Washington Post

    As environmental campaigners count a record $3.4 trillion of funds pledged to avoiding financial support for the most polluting industries, another group of investors is maintaining their so they can make their voice heard quietly. Instead of selling out, the British insurance company Aviva Plc is speaking to about 40 coal companies and utilities in which it holds shares to persuade them to lower their emissions.

    Comment?

  12. Biggest Loser From Stronger Dollar May Be China, Not U.S.Read the original story

    Dec 8, 2015 | Bloomberg

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Here's a surprise for China critics such as Donald Trump who brand the country a currency manipulator: The biggest loser from a rising dollar won't be the U.S. That's because the Asian nation has tethered its currency for the most part to the greenback to enhance financial stability.

    Comment?

  13. Momentum for Climate Deal Grows as Obama Joins Xi in ParisRead the original story

    Nov 29, 2015 | The Washington Post

    More than 140 world leaders including U.S. President Barack Obama and Xi Jinping of China are gathering in Paris for France's biggest diplomatic event since 1948, striving to reach the first truly global deal to curb greenhouse gases. The two weeks of United Nations-sponsored talks have already gathered pledges to reduce emissions from 177 of the 195 countries involved, signaling broader support for a deal than when envoys last attempted to reach one six years ago.

    Comment?

  14. Would You Pay $19 for a Ticket Out of Airport Hell?Read the original story w/Photo

    Nov 19, 2015 | The Washington Post

    A startup called Freebird will buy you a new seat when the airline gods are angry, no questions asked. But there's a catch-mostly for them.

    Comment?

  15. Would You Pay $19 for a Ticket Out of Airport Hell?Read the original story

    Nov 19, 2015 | The Washington Post

    A Boston-area startup, born of a disastrous ski trip 10 months ago, aims to offer an alternative. For $19 to $34, the company, Freebird, guarantees it will buy you a ticket to your destination, regardless of cost or carrier, if a flight is canceled or delayed more than four hours or a connection is missed due to an airline's delay.

    Comment?

  16. Ex-Biogen R&D Head Williams Thinks Small With Codiak VentureRead the original story

    Nov 17, 2015 | The Washington Post

    Doug Williams, the former head of research at Biogen Inc., believes that good things come in small packages. After four years at the biotech giant, he's moving to a far smaller company to investigate a technology based on tiny containers discharged by cells.

    Comment?

  17. Delta Turns to Partitions for Feel of - Premium Economy' in CoachRead the original story w/Photo

    Nov 16, 2015 | Bloomberg

    Delta Air Lines Inc.'s quest to add a dash of luxury and exclusivity to its priciest economy seats will mean erecting some walls. Once the U.S. government approves, Delta will install partitions to separate its extra-legroom "Comfort+" section from the rest of the main cabin on domestic jets, spokesman Anthony Black said Monday.

    Comment?

  18. Biogen to Fire Workers, Restructure R&D After Difficult YearRead the original story

    Oct 21, 2015 | The Washington Post

    The company said the cuts to its workforce of about 8,000 people will save about $250 million a year. It comes after several periods of disappointing results and a stock price that is down 22 percent this year.

    Comment?

  19. Biogen Under Turnaround Pressure Months After Hitting RecordRead the original story

    Oct 14, 2015 | The Washington Post

    The biotech giant has plummeted 46 percent from that high point, leaving shares down 25 percent this year, compared with a 1.6 percent decline for the Nasdaq Biotechnology Index. Shares closed at $256.04 on Tuesday, the lowest since November 2013.

    Comment?

  20. Biogen Under Turnaround Pressure Months After Hitting a RecordRead the original story

    Oct 14, 2015 | The Washington Post

    Seven months ago, Biogen Inc. shares were soaring to a record as investors flocked to biotech stocks and were tantalized by the prospects of the company's experimental drug for Alzheimer's disease. The biotech giant has plummeted 46 percent from that high point, leaving shares down 25 percent this year, compared with a 1.6 percent decline for the Nasdaq Biotechnology Index.

    Comment?

Cambridge Job Listings
View or post Cambridge job listings on Topix.
Cambridge Real Estate
News, listings, and foreclosures in Cambridge from Topix.
Cambridge Mortgages
Find mortgage rates in Cambridge on Topix.